PL357936A1 - Zastosowanie fulwestrantu w leczeniu opornego raka sutka - Google Patents

Zastosowanie fulwestrantu w leczeniu opornego raka sutka

Info

Publication number: PL357936A1
Authority: PL; Poland
Prior art keywords: fulvestrant; treatment; breast cancer; resistant breast; resistant
Prior art date: 2000-04-05

Application number

PL01357936A

Other languages

English (en)

Other versions

PL201175B1 (pl

Inventor

Beat Thurlimann

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2001-04-02

Publication date

2004-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL357936(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-08-09 Publication of PL357936A1 publication Critical patent/PL357936A1/pl

2009-03-31 Publication of PL201175B1 publication Critical patent/PL201175B1/pl

Links

206010006187 Breast cancer Diseases 0.000 title abstract 2
208000026310 Breast neoplasm Diseases 0.000 title abstract 2
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
229960002258 fulvestrant Drugs 0.000 title abstract 2
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
239000003886 aromatase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL357936A 2000-04-05 2001-04-02 Zastosowanie fulwestrantu do wytwarzania leku do leczenia pacjenta z rakiem sutka PL201175B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008172.9A GB0008172D0 (en)	2000-04-05	2000-04-05	Therapy
PCT/GB2001/001500 WO2001074366A1 (en)	2000-04-05	2001-04-02	Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number	Publication Date
PL357936A1 true PL357936A1 (pl)	2004-08-09
PL201175B1 PL201175B1 (pl)	2009-03-31

Family

ID=9889101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL357936A PL201175B1 (pl)	2000-04-05	2001-04-02	Zastosowanie fulwestrantu do wytwarzania leku do leczenia pacjenta z rakiem sutka

Country Status (28)

Country	Link
US (2)	US20030158166A1 (pl)
EP (2)	EP1272195B1 (pl)
JP (1)	JP2003528919A (pl)
KR (1)	KR100757764B1 (pl)
CN (1)	CN1431905A (pl)
AT (1)	ATE306270T1 (pl)
AU (2)	AU4437201A (pl)
BR (1)	BR0109789A (pl)
CA (1)	CA2403608A1 (pl)
CH (1)	CH1272195H1 (pl)
CZ (1)	CZ303096B6 (pl)
DE (1)	DE60113975T2 (pl)
DK (1)	DK1272195T3 (pl)
EE (1)	EE05026B1 (pl)
ES (1)	ES2248300T3 (pl)
GB (1)	GB0008172D0 (pl)
HU (1)	HU230064B1 (pl)
IL (2)	IL151932A0 (pl)
IS (1)	IS2869B (pl)
MX (1)	MXPA02009744A (pl)
NO (1)	NO329949B1 (pl)
NZ (1)	NZ539603A (pl)
PL (1)	PL201175B1 (pl)
RU (1)	RU2265438C2 (pl)
SK (1)	SK287779B6 (pl)
UA (1)	UA80388C2 (pl)
WO (1)	WO2001074366A1 (pl)
ZA (1)	ZA200207538B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1406662A1 (en) *	2001-07-07	2004-04-14	AstraZeneca AB	Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) *	2005-09-27	2013-10-15	Robert Benson Aylor	Suppression and prevention of tumors
WO2007062093A2 (en) *	2005-11-22	2007-05-31	Incyte Corporation	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
RU2013154048A (ru) *	2011-05-09	2015-06-20	Юниверсити Оф Вирджиния Пэтент Фаундейшн	Композиции и способы лечения рака
CA2836831C (en)	2011-05-20	2015-06-02	Capital, Business Y Gestion De Finanzas S.L.	Pharmaceutical composition
EP3092027A4 (en) *	2014-01-10	2017-09-06	Atossa Genetics Inc.	Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) *	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
EP3681491A4 (en)	2017-09-11	2021-06-30	Atossa Therapeutics, Inc.	PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
JP7384903B2 (ja) *	2018-05-24	2023-11-21	ケーアイファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	フルベストラントのプロドラッグ
WO2021003433A1 (en)	2019-07-03	2021-01-07	Atossa Therapeutics, Inc.	Sustained release compositions of endoxifen
CA3210276A1 (en) *	2020-02-29	2021-09-02	Frances E. Carr	Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362371B1 (en) *	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6465445B1 (en) *	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO329949B1 (no)	2011-01-31
ZA200207538B (en)	2003-12-19
KR20030007501A (ko)	2003-01-23
AU2001244372B2 (en)	2006-02-16
NO20024735D0 (no)	2002-10-02
US20110183949A1 (en)	2011-07-28
IL151932A (en)	2007-07-04
EE05026B1 (et)	2008-06-16
CN1431905A (zh)	2003-07-23
EP1272195B1 (en)	2005-10-12
AU4437201A (en)	2001-10-15
IS6576A (is)	2002-10-01
KR100757764B1 (ko)	2007-09-12
GB0008172D0 (en)	2000-05-24
HUP0300339A2 (hu)	2003-06-28
WO2001074366A1 (en)	2001-10-11
DE60113975D1 (de)	2006-02-23
CZ20023309A3 (cs)	2003-02-12
PL201175B1 (pl)	2009-03-31
BR0109789A (pt)	2003-01-21
ES2248300T3 (es)	2006-03-16
DE60113975T2 (de)	2006-06-22
HUP0300339A3 (en)	2009-01-28
SK14292002A3 (sk)	2003-08-05
HK1051498A1 (en)	2003-08-08
JP2003528919A (ja)	2003-09-30
NZ539603A (en)	2008-02-29
HU230064B1 (hu)	2015-06-29
EP1272195A1 (en)	2003-01-08
CA2403608A1 (en)	2001-10-11
SK287779B6 (sk)	2011-09-05
ATE306270T1 (de)	2005-10-15
DK1272195T3 (da)	2006-01-16
MXPA02009744A (es)	2004-02-26
US20030158166A1 (en)	2003-08-21
EP1586323A1 (en)	2005-10-19
IL151932A0 (en)	2003-04-10
CH1272195H1 (pl)	2019-10-15
RU2265438C2 (ru)	2005-12-10
UA80388C2 (en)	2007-09-25
CZ303096B6 (cs)	2012-04-04
NO20024735L (no)	2002-11-27
IS2869B (is)	2014-03-15
EE200200574A (et)	2004-04-15

Publication	Publication Date	Title
AU4437201A (en)	2001-10-15	Use of fulvestrant in the treatment of resistant breast cancer
IL177597A0 (en)	2006-12-10	A kit and an apparatus for treating a patients skin
HUS1500001I1 (hu)	2016-08-29	ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
ATE430570T1 (de)	2009-05-15	Synergistische kombinationstherapie zur krebsbehandlung
AU6147401A (en)	2001-11-26	Compositions and methods for the treatment of cancer
EP1355563A4 (en)	2004-07-21	METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
IL164599A0 (en)	2005-12-18	Combination therapy for the treatment of cancer
KR970704430A (ko)	1997-09-06	전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
MY138883A (en)	2009-08-28	Use of asiatic acid for treatment of cencer
EP1077704A4 (en)	2002-01-30	COMBINATION THERAPY FOR TREATING DEPRESSION
HUP0500424A2 (en)	2007-02-28	Combination therapy for the treatment of cancer
EP1383573A4 (en)	2005-09-14	METHOD AND DEVICE FOR THE TREATMENT OF ANGRYED TISSUE
MXPA04003674A (es)	2004-07-23	Uso mejorado de compuesto antitumoral en terapia de cancer.
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
DE60324431D1 (de)	2008-12-11	Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
IL158206A0 (en)	2004-05-12	Compositions and methods for the prevention and treatment of human prostate cancer
EP1320402A4 (en)	2005-04-27	DEVICE FOR TREATING HEMORRHOIDS AND FOR PROSTATE MASSAGE
PL368035A1 (pl)	2005-03-21	Kompozycje i sposoby leczenia raka
HUP0301123A3 (en)	2007-10-29	Use of exemestane for treatment of hormone-dependent breast cancer
AU2003250912A8 (en)	2004-01-23	Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2002366195A8 (en)	2003-06-10	Use of bisindolmaleimide and gemcitabine for the treatment of cancer
PL354111A1 (en)	2002-12-02	Combined therapy for treating the both depression and anxiety
EP1684795A4 (en)	2009-07-29	METHODS AND AGENTS FOR THE TREATMENT OF CANCER
GB9826603D0 (en)	1999-01-27	Device for treatment, especially putting in plaster, of patients limb
UA28113C2 (uk)	2000-10-16	Спосіб експрес-тестування ефективності реабілітації здоров'я людини